BioOrbit Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$14.1M
- Investors
-
24
BioOrbit General Information
Description
Operator of an in-orbit pharmaceutical manufacturing platform intended for large-scale crystallization of protein drugs in microgravity. The company offers automated crystallization hardware and microgravity-based crystal formation capabilities, enabling pharmaceutical companies and research institutions to develop protein drug crystals for biologic drug manufacturing.
Contact Information
Website
www.bioorbit.comCorporate Office
- Busworks 39-41 North Road
- Office 404
- London N7 9DP
- England, United Kingdom
Corporate Office
- Busworks 39-41 North Road
- Office 404
- London N7 9DP
- England, United Kingdom
BioOrbit Timeline
BioOrbit Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Seed Round | 01-May-2026 | $14.1M | Completed | Generating Revenue | ||
| 10. Accelerator/Incubator | 11-Sep-2025 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 01-Sep-2025 | Completed | Generating Revenue | |||
| 8. Seed Round | 09-Jun-2025 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 6. Accelerator/Incubator | 04-Dec-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 10-Sep-2024 | Completed | Startup | |||
| 4. Accelerator/Incubator | 08-Dec-2023 | Completed | Startup | |||
| 3. Accelerator/Incubator | 23-Nov-2023 | Completed | Startup | |||
| 2. Accelerator/Incubator | 07-Nov-2023 | Completed | Startup |
BioOrbit Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed -5 | ||||||||
| Seed -3 | ||||||||
| Seed -3 | ||||||||
| Seed -2 | ||||||||
| Seed -1 | 774,832 | $0.000134 | $13.9 | $13.9 | 1x | $13.9 | 35.07% | |
| Ordinary | 30,918 | $0.000134 | $4.35 | $4.35 | 1x | $4.35 | 1.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
BioOrbit Patents
BioOrbit Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025224708-A1 | Systems and methods for continuous flow reactors for crystallisation in microgravity environments | Pending | 26-Apr-2024 |
BioOrbit Signals
BioOrbit Investors (24)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alphaaero | Corporate Venture Capital | Minority | ||
| Alpha Funds | Venture Capital | Minority | ||
| Auxxo | Angel Group | Minority | ||
| Breega | Venture Capital | Minority | ||
| Angel (individual) | Minority |
BioOrbit FAQs
-
When was BioOrbit founded?
BioOrbit was founded in 2023.
-
Where is BioOrbit headquartered?
BioOrbit is headquartered in London, United Kingdom.
-
What is the size of BioOrbit?
BioOrbit has 7 total employees.
-
What industry is BioOrbit in?
BioOrbit’s primary industry is Other Devices and Supplies.
-
Is BioOrbit a private or public company?
BioOrbit is a Private company.
-
What is the current valuation of BioOrbit?
The current valuation of BioOrbit is .
-
What is BioOrbit’s current revenue?
The current revenue for BioOrbit is .
-
How much funding has BioOrbit raised over time?
BioOrbit has raised $14.1M.
-
Who are BioOrbit’s investors?
Alphaaero, Alpha Funds, Auxxo, Breega, and are 5 of 24 investors who have invested in BioOrbit.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process